PapersPMID:33669954
Effects of Curcumin on Glycemic Control and Lipid Profile in Polycystic Ovary Syndrome: Systematic Review with Meta-Analysis and Trial Sequential Analysis.
- findings
- 2
- compound
- 1
- endpoints
- 2
curcumin- Study, every finding
- meta-analysis
- Dose studied, every finding
- 500 mg once per day to 500 mg three times per day across trials
- Population, every finding
- Adult women with polycystic ovary syndrome (Rotterdam criteria); pooled curcumin against placebo, 2 randomised trials reporting lipids
No finding here moved its endpoint.
What did not
How to read these marks →“In contrast, there is no statistically significant difference in the improvement in LDL (MD: −6.02, 95% CI: −26.66 to 14.62; P = 0.567; I2 = 86%) and triglyceride (MD: 8.22, 95% CI: −26.10 to 42.53; P = 0.639; I2 = 75%) between patients taking curcumin and those taking placebo.”
- No detected effect on triglycerides
moderatereplicated ×5
- Effect
- 8.22 mean difference, 95% CI −26.1 to 42.53
- No detected effect on LDL cholesterol
moderatereplicated ×6
- Effect
- −6.02 mean difference, 95% CI −26.66 to 14.62
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Adult patients with PCOS (Rotterdam criteria) in 3 RCTs comparing curcumin (500 mg once to three times per day, 6 to 12 weeks) with placebo
- Participants
- 168
- Comparator
- placebo
- Duration
- not reported
- Endpoints measured
- 8